Compare ASA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASA | CRVS |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2003 | 2016 |
| Metric | ASA | CRVS |
|---|---|---|
| Price | $67.25 | $18.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.17 |
| AVG Volume (30 Days) | 46.6K | ★ 966.0K |
| Earning Date | 06-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.67 | $3.17 |
| 52 Week High | $83.20 | $26.95 |
| Indicator | ASA | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 64.18 |
| Support Level | $65.80 | $16.15 |
| Resistance Level | $73.60 | $18.73 |
| Average True Range (ATR) | 2.36 | 1.02 |
| MACD | 0.55 | 0.39 |
| Stochastic Oscillator | 59.28 | 70.07 |
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.